N/A N=90 FGF-21 Levels and RMR in Children and Adolescents With Hashimoto's Thyroiditis (THYROMETABOL)
Hashimoto Disease
Primary: Fibroblast Growth Factor 21 (FGF-21) — 182.71; 217.36; 198.43 pg/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=173 Neurocognitive and Metabolic Effects of Mild Hypothyroidism
Hypothyroidism
Primary: Executive Function — 7.9; 7.5; 8.8 units on a scale
Phase 3 N=61 Early Levothyroxine Post Radioactive Iodine
Graves' Disease
Primary: Number of Participants With Overt Hypothyroidism — 11; 17 Participants — p=0.23
Phase 4 N=30 Preoperative Steroids in Autoimmune Thyroid Disease
Thyroid Diseases
Primary: Thyroid Difficulty Scale Score — 9.8; 9.75 score on a scale
Phase 4 N=11 Hypothyroidism Treated With Calcitonin
Hypothyroidism
Primary: Modified City of Hope Quality of Life Questionnaire for Patients With Thyroid Disease — -36.33 score on a scale
Phase 3 N=1,203 Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy
Subclinical Hypothyroidism · Hypothyroxinemia · Pregnancy
Primary: Intellectual Function of Children at 5 Years of Age in Women Diagnosed With a) Subclinical Hypothyroidism or b) Hypothyroxinemia During the First Half of Pregnancy, or…
Phase 2 N=14 Thyroid and Glucose and Energy Metabolism
Thyroid Diseases
Primary: Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase — 7.26 mg/kg/min
N/A N=12 Treatment Trial of Subclinical Hypothyroidism in Down Syndrome
Down Syndrome · Subclinical Hypothyroidism
Primary: Change in Lipid Panel From Baseline at 6, 12 and 18 Months. — 160; 170; 163; 172 mg/dL
Phase 1 N=12 ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy
Graves Disease
Primary: Occurrence of Treatment Emergent Adverse Events (TEAE), Serious Adverse Events (SAE), and Laboratory Abnormalities up to Week 22 Compared to Baseline. — 311; 293; 18; 0…
Phase 2 N=7 Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations
Insulin Resistance · Diabetes Mellitus · Abnormal Glucose Metabolism
Primary: Total Body Glucose Disposal in the Fasting State — 21.47 μmol/kg LBM (Lean Body Mass)/min
Phase 2 N=13 Energy Metabolism in Thyroidectomized Patients
Thyroid Goiter · Hypothyroidism · Thyroid Cancer
Primary: Short Term Change in Weight — 1.7; -0.76 Kilogram
N/A N=14 Mechanistic Study of Subclinical Hypothyroidism In the Elderly
Subclinical Hypothyroidism
Primary: TSH Area Under the Curve — 267.8; 266.2 μIU*min/mL
Phase 4 N=66 Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
Hypothyroidism;Postablative
Primary: Thyroid Stimulating Hormone (TSH) — -0.676 mIU/L — p=<0.0001
Phase 4 N=36 Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease
Graves Disease · Hyperthyroidism
Primary: Blood Loss During Surgery — 61.67; 161.67 mL
N/A N=142 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis
Differentiated Thyroid Cancer · Osteoporosis
Primary: Percent Change of Bone Mineral Density in Lumbar and Hip — 3.0; 3.2; 3.8; 5.1 percentage change
N/A N=38 Efficacy of a Spirulina Supplement for Amelioration of Benign ThYroid Nodules
Benign Thyroid Nodule
Primary: Percent Change in Area of Thyroid Nodules — -19.98; -9.31 percentage change — p=0.047
Phase 2 N=284 A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants
Hypothyroidism · Thyroid Disease · Euthyroid
Primary: Percentage of Participants With a Sustained TSH Response — 60.76; 75.92 percentage of participants
Phase 2 N=46 Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
Hypothyroidism
Primary: Dose Conversion Factor — 4.24 Ratio
N/A N=68 Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism
Congenital Hypothyroidism
Primary: Dose Adjustments — 2.5; 2.4 Number of dose adjustments
Phase 3 N=70 Role of Levothyroxine Supplementation in Delayed Recovery Following Cardiac Surgery
Cardiac Surgery Intensive Care Treatment · Delayed Recovery From Anaesthesia · Euthyroid Sick Syndrome
Primary: Change in Glasgow Coma Scale (GCS) From Intervention Initiation to ICU Discharge (Δ) — 6.65; 2.69 Score on a scale
N/A N=48 Thyroid Hormone Dose Adjustment in Pregnancy
Pregnancy · Hypothyroidism
Primary: Proportion of Patients in Each Treatment Arm Euthyroid Through Gestation — 24; 21 participants
N/A N=111 Assess Vitamin D Levels in Those With & Without Thyroid Cancer
Thyroid Cancer
Primary: Number of Persons That Are Vitamin D Deficient in the Thyroid Nodule, Thyroid Cancer in Remission, and the Active Thyroid Cancer Groups. — 23; 20; 11 participants…
N/A N=93 Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism
Hyperthyroidism · Hypothyroidism
Primary: Thyroid Extreme CT — 0.89; 1.16 mm
Phase 4 N=37 Rituximab (RTX) Therapy in Patients With Active TAO
Ophthalmopathy, Thyroid-Associated
Primary: Clinical Activity Score (a Composite Measure of Ophthalmological Signs and Symptoms) — 4.25; 2.77; 4.25; 4.20 score on a scale
Phase 1 N=15 Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study
Multiple Sclerosis
Primary: Determine the Maximum Tolerated Dose (MTD) of Oral L-T3 in Subjects With MS — 75 mcg daily with BID dosing
Phase 2 N=52 Nivolumab Plus Ipilimumab in Thyroid Cancer
Thyroid Cancer
Primary: Best Overall Response Rate — 9.4; 0; 30 percentage of participants
Phase 2 N=27 Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer
Thyroid Cancer
Primary: Percentage of Participants With Local-regional Progression-free Survival — 15.2 percentage of all participants
Phase 2 N=28 Developing Oral LT3 Therapy for Heart Failure - HFrEF
Heart Failure With Reduced Ejection Fraction (HFrEF) · Low T3 Syndrome
Primary: Cardiac Rhythm Monitoring by 14 Day Patch Rhythm Assessment — 11; 19 Number of participants with events
N/A N=34 Generic vs. Name-Brand Levothyroxine
Congenital Hypothyroidism · Hypothyroidism
Primary: Thyroid Stimulating Hormone as Primary Endpoint Measured at Initiation of Study, After 8 Weeks of One Drug, and Then 8 Weeks After the Second Drug. — 2.455; 2.131…
Phase 2 N=28 Developing Oral LT3 Therapy for Heart Failure - HFpEF
Heart Failure With Preserved Ejection Fraction · Low Triiodothyronine Syndrome
Primary: Number of Participants With Atrial Fibrillation or Ventricular Tachycardia >=4 Beats — 10; 12 Number of participants with events